International Open Access, Peer-reviewed Platform

Our vision is to provide a global platform for open journals to promote qualitative research publications for
Science, Engineering, Technology and Medicine, with an un-restricted access.

Thomas Muller

Designation:
Professor
Department:
University:
Saint Joseph Hospital
Country:
Germany
Journal Associated: Journal of Neurology, Neurological Science and Disorders Biography:

Research Interest:

Neurodegeneration, Neurodegenerative Diseases, Microglia ,Neuroinflammation, Neuropharmacology, Tau Proteins, TDP-43 Proteinopathies, Amyloid Neuropathies, Neurologic Examination, Neuroplasticity.

List of Publications:

1.    Three new orosomucoid (ORM) variants: revealed by isoelectric focusing and print immunfixation. Weidinger S, Müller T, Schwarzfischer F and Cleve H. Human Genetics 1987; 77: 286 – 288.
   
2.    Functional brain imaging (mapping of EEG) in relation to psychopathologic changes in schizophrenia. Müller T, Dierks T, Fritze J, Maurer K. Psychiatry Research 1989; 29:  419 – 420.   

3.    Mapping des EEG - macht Halluzinationen sichtbar. Müller T, Dierks T, Fritze J, Maurer K. Psycho 1990; 16/3: 189 – 192. 
   
4.    Cholinergic - adrenergic balance: Part 1. Relationship between central and peripheral sensitivities. Fritze J, Sofic E, Müller T, Pfüller H, Lanczik M, Riederer P. Psychiatry Research 1990; 34: 259 – 270.

5.    Cholinergic - adrenergic balance: Part 2. Relationship between drug sensitivity and personality. Fritze J, Sofic E, Müller T, Pfüller H, Lanczik M, Riederer P. Psychiatry Research 1990; 34: 271 – 279.    
   
6.    Alpha2 - adrenoceptor responsivity in depression: effect of chronic treatment with moclebemide, a selective MAO-A-inhibitor, versus maprotiline. Lesch KP, Laux G and Müller T. Journal of Neural Transmission [Suppl] 1990; 32: 457 – 461.    
   
7.    Long-term fluoxetine treatment decreases 5-HT-1a receptor responsivity in obsessive - compulsive disorder.  Lesch KP, Hoh A, Schulte HM, Osterheider M and Müller T. Psychopharmacology 1991; 105: 415 – 420.
   
8.    Erhöhte Prävalenz von Arachnoidalzysten bei psychiatrischen Patienten: Eine retrospektive CT- und MR-Untersuchung. Becker T, Lanczik M, Hofmann E, Müller T, Warmuth-Metz M, Fritze J, Schuhknecht B. Klinische Neuroradiologie 1991; 1: 154 – 160.
   
9.    5-HT-1a receptor-effector system responsitvity in panic disorder. Lesch KP, Wiesmann M, Hoh A, Müller T, Disselkamp-Tietze J, Osterheider M, Schulte HM. Psychopharmacology 1992; 106: 111 – 117.
   
10.    Nimodipine and flunarizine in alcohol withdrawal: an open study. Deckert J, Müller T, Becker T, Lanczik M and Fritze J. Journal of Psychopharmacology 1992; 6(2): 273 – 277.
   
11.    Therapy with central active catechol-O-methyltransferase (COMT)-inhibi-tors: Is addition of monoamine oxidase (MAO)-inhibitors necessary to slow progress of neurodegenerative disorders? Müller T, Kuhn W and Przuntek H. Journal of Neural Transmission [General Section] 1993; 92: 187 – 195.

12.    Impaired colour discrimination in Parkinson's disease. Büttner T, Patzold T, Kuhn W, Müller T, Przuntek H. Neuro-ophthalmology 1994; 14/2: 91 –  95.
   
13.    Achromatopsia as symptom of multiple sclerosis. Müller T, Büttner T, Kuhn W, Przuntek H. Neuro-ophthamology 1994; 14/5: 277 – 278.    
   
14.    Distorted colour discrimination in de-novo parkinsonian patients. Büttner T, Kuhn W, Müller T, Patzold T, Przuntek H. Neurology 1995; 45: 386 – 387.    
   
15.    Palinopsia as sensory epileptic phenomenon. Müller T, Büttner T, Kuhn W, Heinz A, Przuntek H. Acta Neurologica Scandinavica 1995; 91: 433 – 436.    
   
16.    Intravenous application of amantadine and antiparkinsonian efficacy in parkinsonian patients. Müller T, Kuhn W, Quack G and Przuntek H. Journal of Neural Transmission [Suppl] 1995; 46: 407 – 414.    
 
17.    Plasma harman and norharman in Parkinson's disease. Kuhn W, Müller T, Große H and Rommelspacher H. Journal of Neural Transmission [Suppl] 1995; 46: 291 – 296.

18.    Pharmacological effects of dopaminergics and amantadine on colour discrimination in Parkinson's disease. Büttner T, Kuhn W, Müller T, Mc-Monagle U, Przuntek H. Neuro-ophthalmology 1995; 15/3: 135 – 141.
   
19.    Color vision in Parkinson's disease: Missing effect of amantadine sulphate. Büttner T, Kuhn W, Müller T, Patzold T, Przuntek H. Clinical Neuropharmacology 1995; 18/5: 458 – 463.
   
20.    Plasma levels of the -carbolines harman and norharman in Parkinson's disease. Kuhn W, Müller T, Große H, Dierks T and Rommelspacher H. Acta Neurologica Scandinavica 1995; 92: 451 – 454.

21.    Interleukin-1- and interleukin 6 are elavated in the cerebrospinal fluid of Alzheimer's disease and de-novo Parkinson's disease patients. Blum-Degen D, Müller T, Kuhn W, Gerlach M, Przuntek H, Riederer P. Neuroscience Letters 1995; 202 ( 1&2): 17 – 20.

22.    Antioxidative properties of aspirin: dose dependence and clinical implications. Kuhn W, Müller T, Büttner T, Gerlach M. European Journal of Neurology 1996; 3: 275 – 277.

23.    The motor performance test series in Parkinson's disease is influenced by depression. Kuhn W, Heye N, Müller T, Kraus P, Klotz P, Friedrich B, Welter FL and Przuntek H. Journal of Neural Transmission [General Section] 1996; 103: 349 – 354.
   
24.    Elevated levels of harman and norharman in cerebrospinal fluid of parkinsonian patients. Kuhn W, Müller T, Große H, Rommelspacher H. Journal of Neural Transmission [Parkinson's disease and Dementia Section] 1996; 103: 1435 – 1440.    
25.    Sustained-release of levodopa: single dose study of a new formulation. Gerlach M, Kuhn W, Müller T, Klotz P and Przuntek H. Journal of Neural Transmission [General Section] 1996; 103: 717 – 727.

26.    Increased GABA synthesis in skin fibroblasts of patients with Huntington's disease: a possible role of glutamic acid decarboxylase? Gerlach M, Kuhn W, Müller T, Winkel R, Lange H and Przuntek H. European Journal of Neurology 1996; 3: 467 – 470.    
   
27.    Chromatic and achromatic visually evoked potentials in Parkinson's disease. Büttner T, Kuhn W, Müller T, Heinze T, Pühl C, Przuntek H. Electroencephalography and Clinical Neurophysiology 1996; 100: 443 – 447.
   
28.    Visual hallucinosis: the major clinical determinant of distorted chromatic contour perception in Parkinson's disease. Büttner T, Kuhn W, Müller T, Welter FL, Federlein J, Heidbrink K and Przuntek H. Journal of Neural Transmission [General Section] 1996; 103: 1195 – 1203.    
   
29.    Parenteral application of NADH in Parkinson's disease: Clinical improvement partially due to stimulation of endogenous levodopa biosynthesis. Kuhn W, Müller T, Winkel R, Danielczik S, Gerstner A, Häcker R, Mattern C and Przuntek H. Journal of Neural Transmission (1996) 103: 1187 – 1193.
   
30.    Selegiline stimulates biosynthesis of cytokines interleukin-1- and inter-leukin-6. Kuhn W, Müller T, Krüger R and Przuntek H. Neuroreport 1996; 7: 2847 – 2848.
   
31.    Depression in Parkinson's disease: Biogenic amines in CSF of de-novo patients. Kuhn W, Müller T, Gerlach M, Sofic E, Fuchs G, Heye N, Prautsch R and Przuntek H. Journal of Neural Transmission 1996; 103: 1441 – 1445.
   
32.    SPECT-evaluation of the monoamine uptake site ligand [123I](1R)-2-beta-carbomethoxy-3-beta-(4-iodophenyl)-tropane ([123I]--CIT) in untreated patients with suspicion of Parkinson's disease. Eising EG, Müller T, Zander C, Kuhn W, Coenen HH. Journal of Investigative Medicine 1997; 45/8: 448 – 452.   

33.    Distorted colour discrimination in Parkinson's disease is related to severity of the disease. Müller T, Kuhn W, Büttner T, Przuntek H. Acta Neurologica Scandinavica 1997; 96: 293 – 296.    

34.    2-[123I]-Iodolisuride SPET visualizes dopaminergic loss in de-novo parkinsonian patients - is it a marker of striatal presynaptic degeneration? Müller T, Eising EG, Reiners C, Przuntek H, Jacob M, Kuhn W. Nuclear Medicine Communications 1997; 18/12: 1115 – 1121.

35.    [123I--CIT-SPECT visualizes dopamine transporter loss in de-novo parkin-sonian patients. Müller T, Farahati J, Kuhn W, Eising EG, Przuntek H, Reiners C, Coenen HH. European Neurology 1998; 39: 44 – 48.    
   
36.    Selegiline as immunostimulant - a novel mechanism of action? Müller T, Kuhn W, Krüger R and Przuntek H. Journal of Neural Transmission [Suppl] 1998; 52: 321 – 328.
   
37.    Ala30Pro mutation in the gene encoding -synuclein in Parkinson's disease. Krüger R, Kuhn W, Müller T, Woitalla D, Graeber M, Kösel S, Przuntek H, Epplen JT, Schöls L, Riess O. Nature Genetics 1998; 18: 106 – 108.    
   
38.    Plasma levels of (R)- and (S)-salsolinol are not increased in „de-novo” parkin-sonian patients. Müller T, Sällström Baum S, Häussermann P, Woitalla D, Rommelspacher H, Przuntek H & Kuhn W. Journal of Neural Transmission 1998; 105: 239 – 246.
   
39.    Kleine-Levin syndrome and parkinsonian symptoms - a case report. Müller T, Kuhn W, Börnke C, Büttner T and Przuntek H. Journal of Neurological Sciences 1998; 157/2: 214 – 216.

40.    Intravenously administered aspirin in combination with low-dose heparin in acute ischemic stroke: a safety analysis. Büttner T, Hellwig K, Müller T, Kuhn W. Clinical Neuropharmacology 1998; 21/1: 48 – 51.

41.    Platelet monoamine-oxidase-B activity in de-novo and l-dopa treated parkin-sonian patients and controls. Kuhn W, Müller T, Gerstner A, Winkel R and Goetz ME. Canadian Journal of Neurological Sciences 1998; 25: 249 – 251.

42.    Interleukin-6 levels in cerebrospinal fluid inversely correlate to severity of Parkinson's disease. Müller T, Blum-Degen D, Przuntek H and Kuhn W. Acta Scandinavica Neurologica 1998; 98: 142 – 144.
   
43.    High prevalence for parkinsonism after occupational exposure to lead-sulfate batteries. Kuhn W, Winkel R, Woitalla D, Meves S, Przuntek H and Müller T. Neurology 1998; 50: 1885 – 1886.

44.    Colour vision abnormalities do not correlate to dopaminergic nigrostriatal degeneration in Parkinson's disease. Müller T, Kuhn W, Büttner T, Eising E, Coenen H, Haas M and Przuntek H. Journal of Neurology 1998; 245: 659 – 664.

45.    Gehäuftes Auftreten von Bewegungsstörungen unter Fluspirilen. Müller T, Wöhrle M und Kuhn W. Psycho 1998; 24: 625 – 627.

46.    Elevated plasma levels of homocysteine in Parkinson's disease. Kuhn W, Roebroek R,  Blom H, van Oppenraaij D, Przuntek H, Kretschmer A, Büttner T, Woitalla D, Müller T. European Neurology 1998; 40: 225 – 227.
   
47.    Impaired visual function in focal idiopathic dystonia. Büttner T, Dietz M, Przuntek H, Müller T, Welter FL, Kuhn W. European Neurology 1999; 41: 94 – 98.

48.    EEG-generators in Wilson's disease. Dierks T, Kuhn W, Oberle S, Müller T, Maurer K. European Archives of Psychiatry and Clinical Neuroscience 1999; 249 (1): 15 – 20.

49.    Untersuchung zur Reliabilität der deutschen Version des PDQ-39: Ein krankheitsspezifischer Fragebogen zur Erfassung der Lebensqualität von Parkinson-Patienten. Berger K, Broll S, Winkelmann J, Heberlein I, Müller T, Ries V für die FAQT-Studie-Zentren. Aktuelle Neurologie 1999; 26: 184 – 184.

   
 
50.    Analysis of the parkin detection in sporadic and familial Parkinson's disease. Krüger R, Vieira-Säcker AMM, Kuhn W, Müller T, Woitalla D, Schöls L, Przuntek H, Epplen JT and Riess O. Journal of Neural Transmission 1999; 106: 159 – 163.

51.    Increased suceptibility to sporadic Parkinson's disease by a certain combined -synuclein/apolipoprotein E genotype. Krüger R, Vieira-Säcker AMM, Kuhn W, Berg D, Müller T, Kühnl N, Fuchs GA, Storch A, Woitalla D, Przuntek H, Epplen JT, Schöls L and Riess O. Annals of Neurology 1999; 45: 611 –  617.
   
52.    No increase of synthesis of (R)-salsolinol in Parkinson's disease. Müller T, Sällström Baum S, Przuntek H, Rommelspacher H, Kuhn W. Movement Disorders 1999; 14/3: 514 – 515.

53.    Serum levels of neuron-specific enolase and S-100 protein after single tonic-clonic seizures. Büttner T, Lack B, Jäger M, Wünsche W, Kuhn W, Müller T, Przuntek H, Postert T. Journal of Neurology 1999; 246: 459 – 461.

54.    (R)- and (S)-salsolinol are not increased in cerebrospinal fluid of parkinsonian patients. Müller T, Sällström Baum S, Häussermann P, Przuntek H, Rommelspacher H and Kuhn W. Journal of Neurological Sciences 1999; 164: 158 – 162.

55.    Delayed motor response correlates with striatal degeneration in Parkinson's disease. Müller T, Eising EG, Kuhn W, Büttner T, Coenen HH and Przuntek H. Acta Scandinavica Neurologica 1999; 100: 227 – 230.

56.    Colour vision abnormalities and movement time in Parkinson's disease. Müller T, Kuhn W, Büttner T and Przuntek H. European Journal of Neurology 1999; 6: 711 – 715.

57.    Iron deposits in the subthalamic nuclei in Hallervorden Spatz Disease. Müller T, Amoiridis G, Przuntek H, Kuhn W. European Neurology 1999; 42: 240 – 241.

58.    Detection of tolcapone in cerebrospinal fluid of parkinsonian subjects.  Russ H, Müller T, Woitalla D, Rahbar A, Hahn J, Kuhn W. Naunyn Schmiedeberg's Archives of Pharmacology 1999; 360(6): 719 – 720.

59.        -Synuclein in Parkinson's disease and other neurodegenerative disorders. Krüger R, Müller T and Riess O. Journal of Neural Transmission 2000; 107: 31 – 40.

60.    Effects of apomorphine on visual function in Parkinson's disease. Büttner T, Müller T, Kuhn W. Journal of Neural Transmission 2000; 107: 87 – 94.

61.    The activity of catechol-O-methyltransferase (COMT) in parkinsonian patients with „on-off fluctuations“. Woitalla D, Karwacz K, Müller T, Przuntek H and Kuhn W. Journal of Neural Transmission 2000; 107: 105 – 112.

62.    Tolcapone increases maximum concentration of levodopa. Müller T, Woitalla D, Schulz D, Peters S, Kuhn W, Przuntek H. Journal of Neural Transmission 2000; 107: 113  – 119.
63.    Glutathione-S-transferase polymorphism in Parkinson's disease. Rahbar A, Kempkes M, Müller T, Reich S, Welter FL, Przuntek H, Bolt HM, Kuhn W. Journal of Neural Transmission 2000, 107: 331 – 334.

64.    Levodopa in plasma correlates with body weight of parkinsonian patients. Müller T, Woitalla D, Saft C, Kuhn W. Parkinsonism & Related Disorders 2000; 6: 171 – 173.

65.    Elevated plasma levels of homocysteine in dystonia. Müller T, Woitalla D, Hunsdiek A, Kuhn W. Acta Scandinavica Neurologica 2000; 101(6): 388 – 390.

66.    Mutation analysis and association studies of the UCHL1 gene in German Parkinson's disease patients. Wintermeyer P, Krüger R, Kuhn W, Müller T, Woitalla D, Berg D, Becker G, Leroy E, Polymeropoulos M, Berger K, Przuntek H, Schöls L, Epplen JT, Riess O. Neuroreport 2000; 11(10): 2079 – 2082.

67.    Genetic analysis of the a2-macroglobulin gene in early- and late-onset Parkinson's disease. Krüger R, Menezes-Saecker AMV, Schöls L, Kuhn W, Müller T, Woitalla D, Berg D, Berger K, Przuntek H, Epplen JT, Riess O. Neuroreport 2000; 11: 2439 – 2442.

68.    Loss of visual acuity under dopamine substitution therapy. Peters S, Schweibold G, Przuntek H and Müller T. Neuro-ophthalmology 2000; 24 (1): 273 – 277.

69.    Genetic analysis of immunomodulating factors in sporadic Parkinson's disease. Krüger R, Hardt C, Tschentscher F, Jackel S, Kuhn W, Müller T, Werner J, Woitalla D, Berg D, Kuhnl N, Fuchs GA, Santos EJ, Przuntek H, Epplen JT, Schöls L, Riess O. Journal of Neural Transmission 2000; 107(5): 553 – 562.

70.    Correlation between tapping and inserting of pegs in Parkinson’s disease. Müller T, Schäfer S, Kuhn W and Przuntek H. Canadian Journal of Neurological Sciences 2000; 27(4): 311 – 315.

71.    Choice reaction time after levodopa challenge in parkinsonian patients. Müller T, Benz S, Przuntek H.  Journal of Neurological Sciences 2000; 181(1-2): 98 – 103.

72.    Integrity of the blood-cerebrospinal fluid barrier in early Parkinson’s Disease. Häussermann P, Kuhn W, Przuntek H and Müller T. Neuroscience Letters 2001; 300(3): 182 – 184.

73.    SPECT imaging with [123I--CIT in parkinsonism: Comparison of SPECT images obtained by a single and a three-headed gamma camera. Eising EG, Müller T, Freudenberg L, Müller SP, Dutschka K, Sonnenschein W, Przuntek H, Bockisch A. Nuclear Medicine Communications 2001; 22: 145 – 150.

74.    Implant supported denture in a case of Huntington’s disease: Interdisciplinary aspects. Jackowski J, Andrich J, Zöllner A, Jöhren P, Müller T. Special care in Dentistry 2001; 21(1): 15 – 20.

75.    Vascular parkinsonism: a case report and review of the literature. Peters S, Eising EG, Przuntek H, Müller T. Journal of Clinical Neuroscience 2001; 8(3): 268 – 271.
76.    Familial parkinsonism with synuclein pathology–Clinical and PET studies of A30P mutation carriers.  Krüger R, Kuhn W, Leenders KL, Sprengelmeyer R, Müller T, Woitalla D, Portman AT, Maguire RP, Veenma L, Schröder U, Schöls L, Epplen JT, Riess O and Przuntek H. Neurology 2001; 56(10): 1355 – 1362.

77.    Decrease of methionine and S-adenosylmethionine and increase of homocysteine in treated patients with Parkinson‘s disease. Müller T,  Woitalla D, Hauptmann B, Fowler B, Kuhn W. Neuroscience Letters 2001; 308: 54 – 56.

78.    Evaluation of the gamma-synuclein gene in German Parkinson’s disease patients. Krüger R, Schöls L, Müller T, Kuhn W, Woitalla D, Przuntek H, Epplen JT, Riess O. Neuroscience Letters 2001; 310 (2-3): 191 – 193.

79.    Delay of simple reaction time after levodopa intake. Müller T, Benz S, Börnke C. Clinical Neurophysiology 2001; 112 (11): 2133 – 2137.

80.    The association of dopamine agonists with daytime sleepiness, sleep problems and quality of life in PD patients. Happe S, Berger K on behalf of the FAQT-Study Investigators (Blersch W; Eichhorn T; Gasser T, Holinka H; Knecht S; Kupsch A, Müller T, Riess V, Vieregge P, Winkelmann J). Journal of Neurology 2001; 248: 1062 – 1067.

81.    Quantification of the dopaminergic response in Parkinson’s disease. Müller T, Benz S. Parkinsonism & Related Disorders 2002; 8(1): 181 – 186.

82.    Tapping and peg insertion after levodopa intake in treated and de-novo parkinsonian patients. Müller T, Benz S, Przuntek H. Canadian Journal of Neurological Sciences 2002; 29(1): 73 – 77.

83.    3-OMD and homocysteine plasma levels in parkinsonian patients. Müller T, Woitalla D, Fowler B, Kuhn W. Journal of Neural Transmission 2002; 109 (2): 175 – 179.

84.    Progress of visual dysfunction in Parkinson’s disease. Müller T, Woitalla D, Peters S, Kohla K, and Przuntek H. Acta Scandinavica Neurologica 2002; 105(4): 256 – 260.

85.    Apomorphine delays simple reaction time in parkinsonian patients. Müller T, Benz S, Przuntek H. Parkinsonism & Related Disorders 2002; 8 (5): 357 – 360.

86.    Budipine provides additional benefit in parkinsonian patients on a stable optimum dopaminergic drug regime. Przuntek H, Bittkau S, Bliesath H,  Büttner U, Fuchs G, Glaß J, Haller H, Klockgether T, Kraus P,  Lachenmayer L, Müller D, Müller T, Rathay B, Sgonina J, Steinijans V, Teshmar E, Ulm G, Volc D. Archives of Neurology 2002; 59 (5): 803 – 806.

 
87.    Efficacy and safety of entacapone in Parkinson’s disease patients with suboptimal levodopa response: a 6-month randomized placebo-controlled double-blind study in Germany and Austria (Celemon study). Poewe WH, Deuschl G, Gordin A, Kultalahti ER, Leinonen M and the Celomen Study Group. Acta Scandinavica Neurologica 2002; 105(4): 245 – 255.

88.    Polymorphisms in the interleukin-1 alpha and beta genes and the risk for Parkinson’s disease. Schulte T, Schöls L, Müller T, Woitalla D, Berger K, Krüger R. Neuroscience Letters 2002; 236: 70 – 72.

89.    Neuroleptic malignant-like syndrome after rapid switch from bromocriptine to pergolide. Reimer J, Kuhlmann A, Müller T. Parkinsonism & Related Disorders 2002; 9: 115 – 116.

90.    The association between caregiver burden and sleep disturbances in partners of patients with Parkinson’s disease. Happe S, Berger K on behalf of the FAQT-Study Investigators (Blersch W; Eichhorn T; Gasser T, Holinka H; Knecht S; Kupsch A, Müller T, Riess V, Vieregge P, Winkelmann J). Age and Ageing 2002, 31 (5): 349 – 354.

91.    The association between disease severity and sleep-related problems in patients with Parkinson's disease. Happe S, Ludemann P, Berger K, FAQT-Study Investigators (Blersch W; Eichhorn T; Gasser T, Holinka H; Knecht S; Kupsch A, Müller T, Riess V, Vieregge P, Winkelmann J). Neuropsychobiology 2002; 46(2): 90 – 96.

92.    Depressed mood and executive dysfunction in early Parkinson’s disease. Ueckermann J, Daum I, Peters S, Wiebel B, Przuntek H, Müller T. Acta Scandinavica Neurologica 2003; 107(5): 341 – 348.

93.    Intravenous amantadine sulphate application improves complex but not simple motor task performance in patients with Parkinson’s disease. Müller T, Kuhn W, Schulte T, Przuntek H. Neuroscience Letters 2003; 339(1): 25 –28.

94.    Repeated rating improves value of diagnostic dopaminergic challenge tests in Parkinson’s disease. Müller T, Benz S, Börnke C, Russ H and Przuntek H. Journal of Neural Transmission 2003; 110(6): 603 – 609.

95.    Coenzyme Q10 supplementation mildly improves treated patients with Parkinson’s disease. Müller T, Büttner T, Gholipour A, Kuhn W. Neuroscience Letters 2003; 341(3): 201 – 204.

96.    Efficacy and safety of repeated intrathecal triamcinolone acetonide application in progressive multiple sclerosis patients. Hoffmann V, Schimrigk S, Islamova S, Hellwig K, Lukas C, Brune N, Pöhlau D, Przuntek H, Müller T. Journal of Neurological Sciences 2003; 211(1-2): 81 – 84.

97.    Apomorphine reduces BOLD signal in fMRI during voluntary movement in Parkinsonian patients. Peters S, Suchan  B, Rusin J, Daum I, Köster O, Przuntek H, Müller T, Schmid G. Neuroreport 2003; 14 (6): 809 – 812.

98.    Modulation of disease risk according to a cathepsin D/apolipoprotein E genotype in Parkinson’s disease. Schulte T, Böhringer S, Schöls L, Müller T, Fischer C, Riess O, Berger K, Epplen JT, Krüger R. Journal of Neural Transmission 2003; 110 (7): 749 – 755.

99.    Motor impairment influences Farnsworth-Munsell 100 Hue test error scores in Parkinsonian patients. Müller T, Meisel M, Russ H, Przuntek H. Journal of Neurological Sciences 2003; 213: 61 – 65.

100.    Treatment benefit correlates with increase of daily drug costs in Parkinson’s disease clinics. Müller T, Voß B, Hellwig K, Przuntek H. Neurorehabilitation 2003; 18(3): 271 – 275.

101.    Assessment of complex movements reflects dysfunction in Huntington‘s Disease. Saft C, Andrich J, Meisel NM, Przuntek H and Müller T. Journal of Neurology 2003; 250(12): 1469 – 1474.

102.    Mutation analysis of the neurofilament M gene in Parkinson’s disease. Krüger R, Fischer R, Schulte T, Strauss KM, Müller T, Woitalla D, Berg D, Hungs M, Gobbele R, Berger K, Epplen JT, Riess O, Schöls L. Neuroscience Letters 2003; 351(2): 125 – 129.

103.    Differential response in choice reaction time following apomorphine based on prior dopaminergic treatment. Müller T, Benz S, Börnke C, Przuntek H. Acta Scandinavica Neurologica 2004; 109(5): 348 – 354.

104.    Treatment benefit and daily drug costs in Parkinson’s disease clinics. Müller T, Voß B, Hellwig K, Przuntek H. CNS Drugs 2004; 18(2): 105 – 111.

105.    Hyperhomocysteinaemia in treated patients with Huntington‘s Disease. Andrich J, Saft C, Arz A, Schneider B, Agelink MW, Kraus PH, Kuhn W and Müller T. Movement Disorders 2004; 19(2): 226 – 228.

106.    Extended mutation analysis and association studies of Nurr1 (NR4A2) in Parkinson’s disease. Hering R, Petrovic S, Mietz EM, Holzmann C, Berg D, Bauer P, Woitalla D, Müller T, Berger K, Krüger R, Riess O. Neurology 2004; 62: 1231 – 1232.

107.    Levodopa associated homocysteine increase and sural axonal neurodegeneration. Müller T, Renger K, Kuhn W. Archives of Neurology 2004; 61: 657 – 660.

108.    Multicenter, Open-label, Trial of Sarizotan in Parkinson Disease Patients with levodopa-induced Dyskinesias (the SPLENDID Study). Olanow CW, Damier P, Goetz CG, Müller T, Nutt J, Rascol O, Serbanescu A, Deckers F, Russ H. Clinical Neuropharmacology 2004; 27: 58 – 62.

109.    Chronic levodopa intake increases levodopa plasma bioavailability in patients with Parkinson’s disease. Muhlack S, Woitalla D, Welnic J, Twiehaus S,  Przuntek H and Müller T. Neuroscience Letters 2004; 363 [3]: 284 –287.

110.    Methyltetrahydrofolate Reductase polymorphism influences onset of Huntington‘s disease. Brune N, Andrich J, Gencik M, Saft C, Müller T, Valentin S, Przuntek H, Epplen JT. Journal of Neural Transmission 2004; Suppl. 68: 105 – 110.

111.    Worsened motor test performance following acute apomorphine injection in previously untreated patients with Parkinson’s disease. Müller T, Benz S, Börnke C, Muhlack S, Woitalla D and Przuntek H. Journal of Neural Transmission 2004; Suppl. 68: 79 – 87.

112.    Transdermal lisuride delivery in the treatment of Parkinson`s disease.  Woitalla D, Müller T, Benz S, Horowski R and Przuntek H. Journal of Neural Transmission 2004; Suppl. 68: 89 – 95.

113.    Simple movement sequences better correlate to levodopa plasma levels than complex ones. Muhlack S, Konietzka S, Woitalla D, Przuntek H and Müller T. Journal of Neural Transmission 2004; Suppl. 68: 53 – 60.

114.    Congruent deterioration of complex and simple movements in patients with Huntington‘s Disease. Saft C, Andrich J, Meisel NM, Przuntek H and Müller T. Journal of Neural Transmission 2004; Suppl. 68: 97 – 104.

115.    Screening for mutations in Synaptotagmin XI in Parkinson’s disease. Glass AS, Huynh DP, Franck T, Woitalla D, Müller T, Pulst SM, Berg D, Krüger R and Riess O. Journal of Neural Transmission 2004; Suppl. 68: 21 – 28.

116.    Clinical effects of repetitive transcranial magnetic stimulation versus acute levodopa challenge in Parkinson´s disease. Börnke C, Schulte T, Przuntek H and Müller T. Journal of Neural Transmission 2004; Suppl. 68: 61 – 67.

117.    Coenzyme Q10 serum levels in Huntington´s Disease. Andrich J, Saft C, Gerlach M, Schneider B, Arz A, Kuhn W, Müller T. Journal of Neural Transmission 2004; Suppl. 68: 111 – 116.

118.    Differential executive control impairments in early Parkinson’s disease. Ueckermann J, Daum I, Bielawski M, Muhlack S, Peters S, Przuntek H, and Müller T. Journal of Neural Transmission 2004; Suppl. 68: 39 – 51.

119.    Impact of apomorphine on BOLD signal during movement in normals.  Schmid G, Suchan B, Rusin J, Daum I, Köster O, Przuntek H, Müller T and Peters S. Journal of Neural Transmission 2004; Suppl. 68: 69 – 78.

120.    Dopaminergic neurotoxicity of homocysteine and its derivatives in primary mesencephalic cultures. Heider I, Lehmensieck V, Lenk T, Müller T, Storch A. Journal of Neural Transmission 2004; Suppl. 68: 1 – 13.

121.    MTHFR C 677 T polymorphism, folic acid and hyperhomocysteinemia in levodopa treated patients with Parkinson’s disease. Woitalla D, Kuhn W and Müller T. Journal of Neural Transmission 2004; Suppl. 68: 15 – 20.

122.    Treatment of somatoform disorders with St. John’s wort – a randomized, double-blind and placebo-controlled trial. Müller T, Mannel M, Murck H, Rahlfs VW. Psychosomatic Medicine 2004; 66(4): 538 – 547.

123.    Antiapoptotic effects of budipine. Müller T, Przuntek H, Krüger R and Mackowiak A. Journal of Neural Transmission 2004; 111(10-11): 1365 – 1373.

124.    Novel homozygous E64D mutation in DJ1 in early onset Parkinson’s disease (PARK7). Hering R, Strauss KM, Tao X, Bauer A, Woitalla D, Mietz EM, Petrovic S, Bauer P, Schaible W, Müller T, Schöls L, Klein C, Berg D, Meyer PT, Schulz JB, Wollnik B, Tong L, Krüger R and Riess O. Human Mutation 2004; 24(4): 321 - 329.

125.    Xilopar in der Behandlung des Morbus Parkinson. Müller T, Glaß J, Müller D, Link A, Schenk C, Rammes G. Aktuelle Neurologie 2004; 31: 347 – 352.

126.    Efficacy of repeated intrathecal triamcinolone acetonide application in
progressive multiple sclerosis patients with spinal symptoms. Hellwig K, Stein FJ, Przuntek H and Müller T. BMC Neurology 2004; 4:18

127.    Impaired gastric emptying of a solid test meal in patients with Parkinson's disease using 13C-sodium octanoate breath test. Goetze O, Wieczorek J, Müller T, Przuntek H, Schmidt WE, Woitalla D. Neuroscience Letters 2005; 375: 170 – 173.

128.    Efficacy of budipine and placebo in untreated patients with Parkinson’s disease. Müller T, Kuhn W and Przuntek H. Journal of Neural Transmission 2005; 112: 1015 – 1023.

129.    Mutations in the alpha-synuclein gene and Parkinson’s disease – implications from the screening of more than 1900 patients. Berg D, Niwar M, Maass S, Zimprich A, Moeller C, Wüllner U, Klein C, Tan E, Schöls L, Marsh L, Dawson T, Janetzky B, Müller T, Woitalla D, Dufke A, Bauer P, Krüger R, Gasser T, Riess O. Movement Disorders 2005; 20: 1191 – 1194.

130.    Segmentale Schweißsekretionsstörung bei Multisystematrophie. Saft C, Andrich J, Müller T, Przuntek H, Stücker M. Hautarzt 2005: 56(8): 773 – 777.

131.    Loss of function mutations in the gene encoding Omi/HtrA2 in Parkinson’s disease. Strauss KM, Martins LM, Plun-Favreau H, Marx FP, Kautzmann S, Berg D, Gasser T, Wszolek Z, Müller T, Bornemann A, Wolburg H, Downward J, Riess O, Schulz JB and Krüger R. Human Molecular Genetics 2005; 14(15): 2099 – 2111.

132.    Impact of levodopa on reduced nerve growth factor levels in Parkinson’s disease patients. Müller T, Lang UE, Muhlack S, Welnic J, Hellweg R. Clinical Neuropharmacology 2005;28(5): 238 – 240.

133.    Exclusion of PINK1 as candidate gene for the late-onset form of Parkinson’s disease in 2 European populations. Schlitter AM, Kurz M, Larsen JP, Woitalla D, Müller T, Epplen JT, Dekomien G. Journal of Negative Results in BioMedicine 2005, 4: 10.     

134.    Levodopa intake increases plasma levels of S-adenosylmethionine in treated Parkinson’s disease patients. Müller T, Fowler B, Kuhn W. Clinical Neuropharmacology 2005; 28(6): 274 – 276.

135.    Failure to confirm influence of Methyltetrahydrofolate reductase (MTHFR) polymorphisms on age at onset of Huntington disease. Hansen W, Saft C, Andrich J, Müller T, Wieczorek S, Epplen JT, Arning L. Journal of Negative Results in BioMedicine 2005; 4(1): 12.  

136.    Repeat intrathecal triamcinolone acetonide application is beneficial in progressive MS patients. Hoffmann V, Kuhn W, Schimrigk S, Islamova S, Hellwig K, Lukas C, Brune N, Pöhlau D, Przuntek H, and Müller T. European Journal of Neurology 2006; 13: 72 – 76.

137.    Inhibition of catechol-O-methyltransferase contributes to more stable levodopa plasma levels. Müller T, Erdmann C, Muhlack S, Bremen D, Przuntek H, Woitalla D. Movement Disorders 2006; 21 (3): 332 – 336.

138.    Parkin gene variations in late-onset Parkinson’s disease: Comparison between Norwegian and German cohorts. Schlitter AM, Kurz M, Larsen JP, Woitalla D, Müller T, Epplen JT, Dekomien G. Acta Scandinavica Neurologica 2006; 113(1): 9 – 13.

139.    Transdermal rivastigmine treatment does not worsen impaired performance of complex motions in patients with Alzheimer’s disease. Muhlack S, Przuntek H, and Müller T. Pharmacopsychiatry 2006; 39: 16 – 19.

140.    The DONPAD-Study – Treatment of dementia in patients with Parkinson's disease with donepezil. Müller T, Welnic J, Fuchs G, Ebersbach G, Baas H, Reichmann H. Journal of Neural Transmission 2006; Suppl. 71: 27 – 30.

141.    Predictors of gastric emptying in Parkinson’s disease. Goetze O, Wieczorek J, Müller T, Schmidt WE, Woitalla D. Neurogastroenterology and Motility 2006; 18(5): 369 – 375.

142.    Assessment of simple movements reflects impairment in Huntington‘s Disease. Saft C, Andrich J, Meisel NM, Przuntek H and Müller T. Movement Disorders 2006; 21 (8): 1208 – 1212.

143.    Impact of gastric emptying on levodopa pharmacokinetics in Parkinson’s disease patients. Müller T, Erdmann C, Bremen D, Schmidt WE, Muhlack S, Woitalla D and Goetze O. Clinical Neuropharmacology 2006; 29(2): 61 – 67.

144.    Entacapone improves complex movement performance in patients with Parkinson’s disease. Müller T, Erdmann C, Muhlack S, Bremen D, Przuntek H, Woitalla D. Journal of Clinical Neuroscience 2007; 14 (5): 424 – 428.

145.    Levodopa availability improves with progression of Parkinson’s disease. Woitalla D, Goetze O, Kim JI, Nikodem AB, Schmidt WE, Przuntek H and Müller T. Journal of Neurology 2006; 253(9): 1221 – 1226.

146.    Pharmacokinetic behaviour of levodopa and 3-O-methyldopa after repeat administration of levodopa/carbidopa with and without entacapone in patients with Parkinson’s disease. Müller T, Erdmann C, Muhlack S, Bremen D, Przuntek H, Goetze O, Woitalla D. Journal of Neural Transmission 2006; 113(10): 1441 –1448.

147.    Tolcapone decreases plasma levels of S-adenosyl-L-homocysteine and homocysteine in treated Parkinson’s disease patients. Müller T, Kuhn W. European Journal of Clinical Pharmacology 2006; 62 (6): 447 – 450.

148.    Repeat intrathecal triamcinolone acetonide application reduces acute occurring painful dysesthesia in patients with relapsing remitting multiple sclerosis. Hellwig K, Lukas C, Brune N, Hoffmann V, Schimrigk S, Przuntek H and Müller T. ScientificWorldJournal 2006; 6: 460 – 465.

149.    Efficacy of mitoxantrone and intrathecal triamcinolone acetonide treatment in chronic progressive multiple sclerosis patients. Hellwig K, Lukas C, Schimrigk S, Hoffmann V, Brune N, Przuntek H and Müller T. Clinical Neuropharmacology 2006; 29(5): 286 – 289.

150.    Patient evaluation of a home diary to assess duration and severity of dyskinesia in Parkinson’s disease. Hauser R, Russ H, Haeger DA, Bruguiere-Fontenille M, Müller T, Wenning GK. Clinical Neuropharmacology 2006; 29(6): 322 – 330.

151.    Mutation analysis of the seven in absentia homolog 1 (SIAH1) gene in Parkinson’s disease. Franck T, Krüger R, Woitalla D, Müller T, Engelender S and Riess O. Journal of Neural Transmission 2006; 113(12): 1903 – 1908.

152.    Acute levodopa administration reduces cortisol release in patients with Parkinson’s disease. Müller T, Welnic J, Muhlack S. Journal of Neural Transmission 2007; 114(3): 347 – 350. 

153.    Sarizotan as a treatment for dyskinesias in Parkinson’s disease: a double-blind placebo controlled trial. Goetz CG, Damier P, Hicking C, Laska E, Müller T, Olanow CW, Rascol O, Russ H. Movement Disorders 2007; 22(2): 179 – 186.

154.    Sensitivity and specificity of dopamine transporter imaging with ¹²³I-FP-CIT SPECT in dementia with Lewy bodies: a phase III, multicentre study. McKeith I, O’Brien J, Walker Z, Tatsch K, Booij J, Darcourt J, Padovani A, Giubbini R, Bonuccelli U, Volterrani D, Holmes C, Kemp P, Tabet N, Meyer I, Reininger C for the DLB Study Group. Lancet Neurology 2007; 6(4): 305 – 313.

155.    Acute levodopa intake and associated cortisol decrease in patients with Parkinson's disease. Müller T and Muhlack S. Clinical Neuropharmacology 2007; 30 (2): 101 –106.

156.    Assessment of simple movements and progression of Huntington‘s disease. Andrich J, Saft C, Ostholt N and Müller T. Journal of Neurology, Neurosurgery & Psychiatry 2007; 78(4): 405 – 407.

157.    Exercise improves efficacy of levodopa in patients with Parkinson’s disease. Muhlack S, Woitalla D and Müller T. Movement Disorders 2007; 22(3): 427 – 430.
   
158.    A randomized, double-blind, placebo-controlled trial on symptomatic effects of coenzyme Q 10 in Parkinson's disease. Storch A, Jost W, Vieregge P, Spiegel J, Greulich W, Durner J, Müller T, Kupsch A, Henningsen H, Oertel WH, Fuchs G, Kuhn W, Niklowitz P, Koch R, Herting B, Reichmann H, for the German Coenzyme Q10 Study Group. Archives of Neurology 2007; 64(7): 938 – 944.

159.    Complex movement behaviour and progression of Huntington‘s disease. Andrich J, Saft C, Ostholt N and Müller T. Neuroscience letters 2007; 416(3): 272 – 274.

160.    Prevalence and treatment strategies of dyskinesia in patients with Parkinson’s disease. Müller T, Woitalla D, Russ H, Hock K, Haeger DA. Journal of Neural Transmission 2007; 114(8): 1023 – 1026.

161.    Comparison of 200 mg retarded release levodopa/carbidopa - with 150 mg levodopa/carbidopa/entacapone application: Pharmacokinetics and efficacy in patients with Parkinson’s disease. Müller T, Kolf K, Ander L, Woitalla D and Muhlack S. Journal of Neural Transmission 2007; 114(11): 1457 – 1462.

162.    Endurance exercise modulates levodopa induced growth hormone release in patients with Parkinson's disease. Müller T, Welnic J, Woitalla D and Muhlack S. Neuroscience letters 2007; 422(2): 119 – 122.

163.    Verbesserung der Alltagsfertigkeiten von Parkinson-Patienten durch Behandlung mit Stalevo (Levodopa/Carbidopa/Entacapon). Müller T, Roscher T, Mehl C. Thieme Drug Report 2007; 2: 4 – 10.

164.    FMR1 Alleles in Parkinson's disease: Relation to Cognitive Decline and Hallucinations, a Longitudinal Study. Kurz MW, Schlitter AM, Klenk Y, Müller T, Larsen JP, Aarsland D, Dekomien G. Journal of Geriatric Psychiatry and Neurology 2007; 20; 2: 89 – 92.

165.    Association of Parkinson's disease with symptoms of attention deficit hyperactivity disorder in childhood. Walitza S, Melfsen S, Herhaus G, Scheuerpflug P, Warnke A, Müller T, Lange KW, Gerlach M. Journal of Neural Transmission 2007; Suppl. (72): 311 – 315.

166.    Time processing in Huntington's disease: A Group-Control Study. Beste C, Saft C, Andrich J, Müller T, Gold R, Falkenstein M. Plos One 2007; 2(12):e1263.

167.    The management approaches to dyskinesia vary from country to country. Woitalla D, Müller T, Russ H, Hock K, Haeger DA. Neuroepidemiology 2007; 29(3-4): 163 –169. 

168.    Allergic and non-allergic delayed infusion reactions during natalizumab therapy. Hellwig K, Schimrigk S, Fischer M, Haghikia A, Müller T, Chan A and Gold R. Archives of Neurology 2008; 65 (5): 656 – 658.

169.    Selegiline reduces cisplatin induced neuronal death in neuroblastoma cells. Müller T, Przuntek H, Rieks M and Mackowiak A. Neurological Research 2008; 30(4):417 – 419.

170.    Rapid switch from oral antiparkinsonian combination drug therapy to duodenal levodopa infusion. Meiler B, Andrich J and Müller T. Movement Disorders 2008;23(1):145 – 146.

171.    COMT inhibition improves levodopa associated strength increase in Parkinson’s disease patients. Müller T, Kolf K, Ander L, Woitalla D and Muhlack S. Clinical Neuropharmacology 2008; 31(3): 134 – 140.
   
172.    Deep brain stimulation improves performance of complex instrumental paradigms.  Ellrichmann G, Harati A and Müller T. European Neurology 2008; 60: 32 – 36.

173.    Error processing in patients with Parkinson’s disease: the influence of medication state. Willemssen R, Müller T, Schwarz M, Hohnsbein J and Falkenstein M. Journal of Neural Transmission 2008; 115(3):461 – 468.

174.    Reproductive counselling, treatment and course of pregnancy in 73 German MS patients. Hellwig K, Brune N, Haghikia A, Müller T, Schimrigk S, Schwödiauer V, Gold R. Acta Scandinavica Neurologica 2008; 118(1):24 – 28.

175.    Placebo influences on dyskinesia in Parkinson's disease. Goetz CG, Laska E, Hicking C,  Damier P, Müller T, Nutt J, Olanow CW, Rascol O, Russ H. Movement Disorders 2008; 23(5):700 – 707.

176.    Impact of endurance exercise on levodopa-associated cortisol release and force increase in patients with Parkinson's disease. Müller T, Muhlack S. Journal of Neural Transmission 2008; 115(6):851 – 855.

177.    A comprehensive genetic study of the proteasomal subunit S6 ATPase in German Parkinson's disease patients. Wahl C, Kautzmann S, Krebiehl G, Strauss K, Woitalla D, Müller T, Bauer P, Riess O and Krüger R.  Journal of Neural Transmission 2008; 115(8): 1141 – 1148.

178.    Entacapone improves absorption of a co-administered salt in patients with Parkinson’s disease. Müller T, Woitalla D, Goetze O, Erdmann C. Movement Disorders 2008; 23(10): 1458 – 1461.

179.    Tesofensine (NS 2330), a monoamine reuptake inhibitor, in patients with advanced Parkinson disease and motor fluctuations: the ADVANS Study. Rascol O, Poewe W, Lees A, Aristin M, Salin L, Juhel N, Waldhauser L, Schindler T, Advance Study Group. Archives of Neurology 2008; 65(5): 577 – 583.

 
180.    Protocol for German trial of Acyclovir and corticosteroids in Herpes-simplex-virus-encephalitis (GACHE): a multicenter, multinational, randomized, double-blind, placebo-controlled German, Austrian and Dutch trial [ISRCTN45122933]. Martinez-Torres F, Menon S, Pritsch M, Victor N, Jenetzky E, Jensen K, Schielke E, Schmutzhard E, de Gans J, Chung CH, Luntz S, Hacke W, Meyding-Lamadé U, and the GACHE Investigators. BMC Neurology 2008; 8: 40.

181.    Increase of relapse rate during assisted reproduction technique in patients with multiple sclerosis. Hellwig K, Schimrigk S, Beste C, Müller T, Gold R. European Neurology 2009; 61(2): 65 – 68.

182.    Cysteine elevation in Levodopa treated patients with Parkinson’s disease. Müller T, Kuhn W. Movement Disorders 2009; 24(6): 929 - 932. 

183.    Effects of aging, Parkinson's disease, and dopaminergic medication on response selection and control. Willemssen R, Falkenstein M, Schwarz M, Müller T, Beste C. Neurobiology of Aging 2011;32(2): 327 – 335.

184.    Homocysteine levels after acute levodopa intake in patients with Parkinson’s disease. Müller T, Kuhn W. Movement Disorders 2009; 24(9): 1339 - 1343. 

185.    Response monitoring in de novo patients with Parkinson's disease. Willemsen R, Müller T, Schwarz M, Falkenstein M, Beste C. Plos One 2009; 4(3): e4898

186.    Riluzole treatment, survival and diagnostic criteria in Parkinson plus disorders: the NNIPPS study. Bensimon G, Ludolph A, Agid Y, Vildaihet M, Payan C, Leigh PN, NNIPPS Study Group. Brain 2009; 132: 156 - 171.

187.    Mehr Flexibilität in der Parkinsontherapie durch die sechs Dosisstärken von Levodopa/Carbidopa/Entacapon (Stalevo®). Müller T. Thieme Drug Report 2009; 2: 1 – 10.

188.    Peripheral COMT inhibition prevents levodopa associated homocysteine increase. Müller T, Muhlack S. Journal of Neural Transmission 2009; 116(10): 1253 – 1256.

189.    Tolcapone ist wirksam, sicher und gut verträglich: eine offene, beobachtende Studie. Müller T, Fischer G. Aktuelle Neurologie 2009; 36: 499 – 505.

190.    Diadochokinetic movements differ between patients with Parkinson’s disease and controls. Müller T, Harati A. Journal of Neural Transmission 2010; 117(2): 189 –195.

191.    Effect of exercise on reactivity and motor behavior in patients with Parkinson’s disease. Müller T and Muhlack S. Journal of Neurology, Neurosurgery & Psychiatry 2010; 81: 747 – 753.

192.    Quality of life, caregiver burden and insurance in German patients with Parkinson’s disease. Müller T and Woitalla D. European Journal of Neurology   2010; 17(11):1365-1369.

193.    Cysteinyl-glycine reduction as marker for Levodopa induced oxidative stress in Parkinson’s disease patients. Müller T and Muhlack S. Movement Disorders 2011; 26(3):543-6.

194.    Impact of Oral Fast Release Amantadine on Movement Performance in Patients with Parkinson’s Disease. Muhlack S, Müsch P, Konietzka S, Woitalla D, Przuntek H and Müller T. Pharmaceutics 2010, 2: doi:10.3390

195.    Peripheral biomarkers for diagnosing sporadic Parkinson's disease. Grünblatt E., Zehetmayer S, Jacob CP, Müller T, Jost WH, Riederer P. Journal of Neural Transmission 2010; 117(12): 1387-1393.

196.    Elevation of total homocysteine levels in patients with Parkinson’s disease treated with duodenal Levodopa/Carbidopa gel. Müller T, Jugel C, Ehret R, Ebersbach G, Bengel G, Muhlack S, Klostermann F. Journal of Neural Transmission 2011; 118(9):1329-33.

197.    Inhibition of Catechol-O-methyltransferase modifies acute homocysteine rise during repeated levodopa application in patients with Parkinson’s disease. Müller T, Woitalla D and Muhlack S. Naunyn Schmiedeberg's Archives of Pharmacology 2011; 383(6): 627-633.

198.    Levodopa induces synthesis of nerve growth factor and growth hormone in patients with Parkinson’s disease. Müller T, Hellwig R and Muhlack S. Clinical Neuropharmacology 2011; 34(3):101-103.

199.    Caries and periodontal disease in patients with Parkinson`s disease. Müller T, Palluch G and Jackowski J. Special care in Dentistry 2011; 31(5):178-81.

200.    Pain perception, pain drug therapy and health status in patients with Parkinson’s disease. Müller T, Muhlack S and Woitalla D. Neuroepidemiology. 2011; 37(3-4):183-7

201.    Malnutritional neuropathy under intestinal levodopa infusion. Klostermann F, Jugel C, Müller T, Marzinzik F Journal of Neural Transmission 2012; 119(3):369-72.

202.    Efficacy of parecoxib, sumatriptan, and rizatriptan in the treatment of acute migraine attacks. Müller T, Lohse L. Clinical Neuropharmacology 2011; 34(6):206-9

203.    The economic costs of progressive supranuclear palsy and multiple system atrophy in France, Germany and the United Kingdom. McCrone P, Payan CA, Knapp M, Ludolph A, Agid Y, Leigh PN, Bensimon G; NNIPPS Study Group. PLoS One. 2011;6(9):e24369. Epub 2011 Sep 8

204.     Disease severity and progression in progressive supranuclear palsy and multiple system atrophy: validation of the NNIPPS--Parkinson Plus Scale. Payan CA, Viallet F, Landwehrmeyer BG, Bonnet AM, Borg M, Durif F, Lacomblez L, Bloch F, Verny M, Fermanian J, Agid Y, Ludolph AC, Leigh PN, Bensimon G; NNIPPS Study Group. PLoS One. 2011;6(8):e22293

205.    A new MRI rating scale for progressive supranuclear palsy and multiple system atrophy: validity and reliability. Rolland Y, Vérin M, Payan CA, Duchesne S, Kraft E, Hauser TK, Jarosz J, Deasy N, Defevbre L, Delmaire C, Dormont D, Ludolph AC, Bensimon G, Leigh PN; NNIPPS Study Group. J. Neurol Neurosurg Psychiatry. 2011 Sep;82(9):1025-32

206.    Cognitive impairment in patients with multiple system atrophy and progressive supranuclear palsy. Brown RG, Lacomblez L, Landwehrmeyer BG, Bak T, Uttner I, Dubois B, Agid Y, Ludolph A, Bensimon G, Payan C, Leigh NP; NNIPPS Study Group. Brain. 2010 Aug;133(Pt 8):2382-93

207.    Comparison of gait training versus cranial osteopathy in patients with Parkinson’s disease: a pilot study. Müller T and Pietsch A. Neurorehabilitation 2013; 32(1):135 -140.

208.    Stalevo®: Individuelle Anpassung der Levodopa-Therapie mit 7 Dosistärken. Müller T. Thieme Drug Report 2012; 2: 1 – 10.

209.    Cysteine decrease following acute Levodopa intake in patients with Parkinson’s disease. Müller T, Muhlack S. Neuroscience Letters 2012 Jul 11; 521(1):37 - 39.

210.    Refractory epileptic seizures due to vitamin B6 deficiency in a patient with Parkinson’s disease under duodopa® therapy. Skodda S, Müller T. Journal of Neural Transmission 2013; 120(2):315 -318.

211.    Levodopa increases speed of alternating movements in Parkinson’s disease patients. Müller T, Peters S, Harati A. Journal of Neural Transmission 2013 Feb;120(2):309-13.

212.    Switch from Selegiline to Rasagiline is beneficial in patients with Parkinson’s disease. Müller T, Hoffmann J, Dimpfel W, Oehlwein C. Journal of Neural Transmission 2013; 120(5):761-765.

213.    Methyl group donating vitamins elevate 3-O-methyldopa in patients with Parkinson’s disease.  Müller T, Jugel C, Muhlack S and Klostermann F. Clinical Neuropharmacology 2013 Mar-Apr;36(2):52-54. 

214.    Neuropathy in Parkinson's disease patients with intestinal levodopa infusion versus oral drugs. Jugel C, Ehlen F, Taskin B, Marzinzik F, Müller T; Klostermann F. Plos One Jun 20;8(6):e66639. doi: 10.1371/journal.pone.0066639

215.    Diadochokinetic movements differ between patients with Huntington’s disease and controls. Müller T, Saft C, Andrich J and Harati A. Neurorehabilitation 2013 Sep 9

216.    Oral and Dental health in Huntington's Disease - an observational study. Saft C, Andrich J, Müller T, Becker J and Jackowski J. BMC Neurology 2013 Sep 3;13(1):114

217.    Neuropsychological effects of deep brain stimulation for Parkinson`s disease. Harati A, Müller T. Surgical Neurology International 2013; 4: S443 - 447

218.    Chronic Monoamine Oxidase-B Inhibitor treatment blocks Monoamine Oxidase-A Enzyme Activity. Bartl J*, Müller T*, Grünblatt E, Gerlach M, Riederer P Journal of Neural Transmission 2013  * equal first authors

219.    Reduction in the free radical status and clinical benefit of repeated intrathecal triamcinolone acetonide application in progressive multiple sclerosis patients. Müller T,  Herrling T, Lütge S, Küchler M, Lohse L, Rothe H, Haas T, Marg M, Öhm G, and Jung K. Clinical Neuropharmacology 2014 Jan-Feb;37(1):22-5

220.    Levodopa related cysteinyl-glycine and cysteine reduction with and without Catechol-O-methyltransferease inhibition in Parkinson’s disease patients. Müller T, Muhlack S. Journal of Neural Transmission 2014; 121(6):643-8

221.    Photoreceptor layer thinning in idiopathic Parkinson's disease Roth NM, Saidha S, Zimmermann H, Brandt AU, Isensee J, Benkhellouf-Rutkowska A, Dornauer M, Kühn AA, Müller T, Calabresi PA, Paul F. Movement Disorders 2014;29(9):1163-70

222.    Fewer fluctuations, higher maximum concentration and better motor response of levodopa with catechol-O-methyltransferase inhibition. Muhlack S, Herrmann L, Salmen S, Müller T. Journal of Neural Transmission 2014;121(11):1357-66

223.    Tolcapone addition improves Parkinson's disease associated nonmotor symptoms. Müller T and for the TANIMOS Study Investigators. Therapeutic Advances in Neurological Disorders Mar 2014;7(2): 77–82

224.    Quantitative EEG Changes in Patients with Parkinson’s Disease during Therapy with Rasagiline. Dimpfel W, Oehlwein C, Hoffmann JA, Müller T. Advances in Parkinson’s disease 2014; 2; 22 -34 DOI: 10.4236/apd.2014.33005. 

225.    One time intrathecal triamcinolone acetonide application increases reduced proteins in cerebrospinal fluid of progressive multiple sclerosis patients. Müller T, Herrling T, Lütge S, Lohse L, Öhm G and Jung K  Folia Neuropatholiciga in press

226.    Decreased levels of repulsive guidance molecule A in association with beneficial effects of repeated intrathecal triamcinolone acetonide application in progressive multiple sclerosis patients. Müller T, Barghorn S, Lütge S, Haas T, Mueller R, Gerlach B, Öhm G, Eilert K, Trommer I, Mueller BK. Journal of Neural Transmission 2014;



Übersichtsarbeiten 

227.    Therapeutische Ansätze zur neurodegenerativen Protektion. Gerlach M, Kuhn W, Müller T und Riederer P. Aktuelle Neurologie 1994; 21: 151 – 161.

228.    Neuroimmune mechanisms in Parkinson's disease. Kuhn W and Müller T. Journal of Neural Transmission [Suppl] 1995; 46: 229 – 234.

229.    Exogenous stimulation of NGF synthesis by catecholamines and their analogues. Kuhn W and Müller T. Journal of Neural Transmission [Suppl] 1995; 46: 189 – 192.

230.    Die antioxidative Potenz von Salizylsäure in Rotwein. Kuhn W, Müller T, Büttner T, Gerlach M, Kemen M. Aktuelle Ernährungsmedizin 1996; 21: 211 – 212.

231.    The clinical potential of deprenyl in neurologic and psychiatric disorders. Kuhn W and Müller T. Journal of Neural Transmission [Suppl] 1996; 48: 7 – 15.

232.    The neuroimmune hypothesis in Parkinson's disease. Kuhn W, Müller T, Nastos I, Poehlau D. Reviews in the Neurosciences 1997; 8: 29 – 34.

233.    Aktuelle Therapie der idiopathischen Parkinson-Erkrankung.  Teil 1: Diagnostik, Therapierichtlinien, Standard-Pharmakotherapie, Physiotherapie. Müller T, Kuhn W, Przuntek H. Fortschritte der Medizin 1997; 115/13: 28 – 34.
   
234.    Aktuelle Therapie der idiopathischen Parkinson-Erkrankung. Teil 2: Neuere und alternative Therapieverfahren. Müller T, Kuhn W, Przuntek H. Fortschritte der Medizin 1997; 115/13: 37 – 41.
   
235.    Aktuelle Therapie der idiopathischen Parkinson-Erkrankung. Nicht-motorische Symptome des Morbus Parkinson. Müller T, Kuhn W, Przuntek H. Fortschritte der Medizin 1997; 115/14: 45 – 48.

236.    Therapie des Morbus Parkinson Teil 1: Standardtherapie motorischer und nichtmotorischer Symptome. Kuhn W, Müller T. Fortschritte Neurologie und Psychiatrie 1997; 65/8: 361 – 374.
   
237.    Therapie des Morbus Parkinson Teil 2: Neue Therapiekonzepte für die Behandlung motorischer Symptome. Kuhn W, Müller T. Fortschritte Neurologie und Psychiatrie 1997; 65/8: 375 – 385.

238.    Budipin. Müller T. Aktuelle Neurologie 1998; 25: 310 – 318.

239.    Clinical efficacy of budipine in Parkinson's disease. Przuntek H and Müller T. Journal of Neural Transmission [Suppl 52] 1999; 56: 75 – 82.

240.    Kommentar zu: Falling asleep at the wheel: motor vehicle mishaps in persons taking pramipexole and ropinirole. Müller T. Psycho 1999; 25: 530 – 532.

241.    Hirninfarkt-Hemmung der Thrombozytenaggregation zur Sekundärprophylaxe. Müller T. Medizin im Bild. Sonderausgabe: Neue Therapieansätze bei ZNS-Erkrankungen. 2/2000: 38 – 41.

242.    Status quo der medikamentösen Optionen in der Parkinson-Therapie (Teil I). Müller T, Kuhn W. ZNS & Schmerz 2001; 1/01: 17 – 23.

243.    Status quo der medikamentösen Optionen in der Parkinson-Therapie (Teil II). Müller T, Kuhn W. ZNS & Schmerz 2001; 2/01: 22 – 28.

244.    Non-dopaminergic drug treatment of Parkinson’s disease. Müller T. Expert Opinion of Pharmacotherapy 2001; 2(4): 557 –  572.

245.    Drug treatment of non motor symptoms in Parkinson’s disease. Müller T. Expert Opinion of Pharmacotherapy 2002; 3(4): 381 – 388.

246.    Therapeutische Effizienz von COMT-Hemmern. Müller T. ZNS & Schmerz 2002; 3/02: 20 – 26.

247.    CPI-1189. Müller T. Current Opinion on Investigational Drugs 2002; 3(2): 1763 – 1767.

248.    Dopaminergic substitution in Parkinson’s Disease. Müller T. Expert Opinion of Pharmacotherapy 2002; 3(10): 1393 – 1403.

249.    Therapie des Morbus Parkinson mit retardiertem Levodopa/Carbidopa. Müller T, Kungel M, Rink P. PsychoNeuro 2003; 29: 462 – 468.

250.    Die fixe Kombination von Levodopa/Carbidopa mit Entacapone in der Parkinsontherapie. Müller T. und Sieb JP. Nervenheilkunde 2004; 23: 174 – 180.

251.    Mood disorders in early Parkinson’s disease. Müller T. Current opinion in Psychiatry 2004; 17: 191 – 196.

252.    Diagnostic staging of Parkinson’s disease: Conceptual aspects. Przuntek H, Müller T and Riederer P. Journal of Neural Transmission 2004; 111: 201 – 216.

253.    Therapie des Morbus Parkinson unter Kosten- und Qualitätsaspekten. Müller T, Fritze J. Aktuelle Neurologie 2005; 32: 584 – 588.

254.    Behandlung von nichtmotorischen Symptomen im fortgeschrittenen Stadium des Morbus Parkinson. Ellrichmann G, Kuhn W, Müller T. Aktuelle Neurologie 2006;  33: 394 – 402.
   
255.    Kosten- und Qualitätsaspekte in der Therapie des Morbus Parkinson. Müller T, Dodel R, Fritze J. Zeitschrift für Ärztliche Fortbildung und Qualität im Gesundheitswesen 2006; 100: 293 – 297.

256.    Levodopa, motor fluctuations and dyskinesia in Parkinson’s disease. Müller T, Russ H. Expert Opinion of Pharmacotherapy 2006, 7(13): 1715 – 1730.

257.    Dyskinesien bei Morbus Parkinson, Klinik, Ätiologie, Therapie. Ellrichmann G, Russ H und Müller T. Fortschritte Neurologie und Psychiatrie 2007;75(7): 387 – 396.

258.    Tolcapone in the management of Parkinson’s disease. Müller T. Ageing Health 2006; 2(5): 709 – 720.

259.    Präventive und symptomatische Therapie der Demenz bei Morbus Parkinson. Müller T, Ellrichmann G. Neurogeriatrie 2006; 3: 113 – 119.

260.    Rivastigmine in the treatment of patients with Alzheimer’s disease. Müller T. Neuropsychiatric Disease and Treatment 2007; 3: 211 – 218.

261.    Relating mode of action to clinical practice: Dopaminergic agents in Parkinson’s disease. Riederer P, Gerlach M, Müller T, Reichmann H. Parkinsonism & Related Disorders 2007; 13(8): 466 – 479.

262.    Moderne Parkinsontherapie, individuell ausgerichtet statt standardisiert. Müller T. Der Neurologe & Psychiater 2007; 10: 31 – 36.

263.    Trenkwalder C, Boesch S, Ceballos-Baumann A, Dressler D, Eggert K, Gasser T, Honig H, Müller T, Reichmann H, Sieb JP, Storch A, Odin P, Poewe W. Intermittierende Apomorphin-Injektionen als Rescue-Therapie beim fortgeschrittenen M. Parkinson: Konsensusstatement. Nervenarzt 2008; 79(4):475 – 479.

264.    Role of homocysteine in the treatment of Parkinson’s disease. Müller T. Expert Review of Neurotherapeutics 2008; 8(6): 957 – 967.

265.    Pirebedil (Clarium). Müller T. Arzneimittel-, Therapie- Kritik  Medizin und Umwelt 2009; 41: 65 – 69.

266.    Levodopa/carbidopa and entacapone in the treatment of Parkinson’s disease: efficacy, safety and patient preference. Müller T. Patient Preference and Adherence 2009; 3: 1 – 9.

267.    The role of intraspinal steroid application in patients with multiple sclerosis. Müller T. Expert Review of Neurotherapeutics 2009; 9(9): 1279 – 1287.

268.    Possible treatment concepts for the Levodopa related hyperhomocysteinemia. Müller T. Cardiovascular Psychiatry and Neurology vol. 2009, Article ID 969752, 5 pages, 2009. doi:10.1155/2009/969752

269.    The impact of COMT-inhibition on gastrointestinal levodopa absorption in patients with Parkinson’s disease. Müller T. Clinical Medicine Insights: Therapeutics 2010; 2: 155 – 168.

270.    New small molecules for the treatment of Parkinson's disease. Müller T. Expert Opinion on Investigational Drugs 2010; 19: 1077 – 1086.

271.    Entacapone. Müller T. Expert Opinion on Drug Metabolism & Toxicology 2010; 6: 983 – 993. 

272.    Motor complications, levodopa metabolism and progression of Parkinson's disease. Müller T. Expert Opinion on Drug Metabolism & Toxicology 2011; 7(7):847 - 855.

273.    Stellenwert der Catechol-O-Methyltransferase-Hemmung in der modernen Parkinson-Therapie. Salmen S., Müller T, Muhlack S. Aktuelle Neurologie 2011; 38: 1 – 8.

274.    Drug Therapy in patients with Parkinson’s disease. Translational Neurodegeneration 2012; 1: 1 - 10.

275.    Psychiatric, non motor aspects of Parkinson’s disease. Müller T, Gerlach M, Youdim MBH, and Riederer P. In Schlaepfer and Nemeroff (eds) Handbook of Clinical Neurology: Neurobiology of Psychiatric Disease 2012; 106: 477 – 490.

276.    Subkutane Apomorphin-Dauerinfusion zur Behandlung des fortgeschrittenen Morbus Parkinson mit Wirkfluktuationen. Expertenkonsensus. Ceballos-Baumann A, Ebersbach G, Müller T, Nikkah G, Sieb JP, Steigerwald F, Storch A, Warnecke T, Winkler J, Wolters A. Thieme Drug Report 2012; 4 (7): 1 – 12.

277.    Peripheral neuropathy in Parkinson's disease: levodopa exposure and implications for duodenal delivery. Müller T, van Laar T, Cornblath DR, Odin P, Klostermann F, Grandas FJ, Ebersbach G, Urban PP, Valldeoriola F, Antonini A. Parkinsonism and Related Disorders 2013: May;19(5):501 – 507.

278.    Detoxification and antioxidative therapy for levodopa induced neurodegeneration in Parkinson’s disease. Müller T. Expert Review of Neurotherapeutics 2013: 13(6):707-718

279.    Pharmaharmacokinetic Considerations for the Use of Levodopa in the Treatment of Parkinson Disease: Focus on Levodopa/Carbidopa/Entacapone for Treatment of Levodopa-Associated Motor Complications. Müller T. Clinical Neuropharmacology 2013: 36(3):84 – 91.

280.    Suitability of the adenosine antagonist istradefylline for the treatment of Parkinson's disease: pharmacokinetic and clinical considerations. Müller T. Expert Opin Drug Metab Toxicol. 2013 Aug;9(8):1015-24

281.    Current status of safinamide for the drug portfolio of Parkinson’s disease therapy. Müller T. Expert Review of Neurotherapeutics 2013 Sep;13(9):969-77.

282.    Morbus Parkinson – Erkennen und richtig behandeln. Müller T. Heilberufe/ Das Pflegemagazin 2013; 65(10): 30  - 34.

283.    PK/PD evaluation of rasagiline mesylate for Parkinson's disease. Müller T. Expert Opinion on Drug Metabolism & Toxicology 2014 Oct;10(10):1423-32







 
Research Letters and comments

284.    Neuroleptic malignant syndrome after clozapine and carbamazepine. Müller T, Becker T, Fritze J. Lancet 1988; 8626/8627: 1500 – 1501.

285.    Malignes neuroleptisches Syndrom. Müller T, Becker T, Fritze J. Deutsche Medizinische Wochenschrift 1989; 114: 442 – 443.

286.    Anticonvulsants combined with nifedipine for epilepsy in adults. Sofic E, Müller T, Gavranovic M, Bilalbegovic Z. American Journal of Psychiatry 1991; 148/6: 808 – 809.

287.    Aspirin as free radical scavenger - consequences for therapy of cerebro-vascular ischemia. Kuhn W, Müller T, Büttner T, Gerlach M. Stroke 1995; 26/10: 1959 – 1960.

288.    Parkinsonism unmasked by lovastatin. Müller T, Kuhn W, Pöhlau D, Przuntek H. Annals of Neurology 1995; 37/5: 685 – 686.

289.    Fluspirilen - ein unbedenklicher Wochentranquilizer? Kuhn W, Wöhrle M, Müller T, Welter F. Nervenarzt 1997; 68: 528.

290.    Antipyretic therapy in acute stroke. Büttner T, Müller T, Hellwig K, Meves S, Kuhn W. Lancet 1998; 352: 740.

291.    Hyperhomocysteinaemia in Parkinson's disease. Kuhn W, Roebroek R, Blom H, van Oppenraaij D, Müller T. Journal of Neurology 1998; 245: 811 – 812.

292.    Central pontine myelinolysis causes bilateral loss of deep sensitivity and pseudochoreoathetosis. Federlein J, Postert T, Przuntek H, Müller T. Journal of Neurology, Neurosurgery & Psychiatry 1998; 65/4: 607 – 608.

293.    Tolcapone and neurotoxicity in Parkinson's disease. Kuhn W, Woitalla D, Gerlach M, Russ H, Müller T. Lancet 1998; 352: 1313 – 1314.

294.    Nigral endothelial dysfunction, homocysteine and Parkinson's disease. Müller T, Werne B, Fowler B, Kuhn W. Lancet 1999; 354: 126 – 127.

295.    Plasma homocysteine and MTHFR C677T genotype in levodopa-treated patients with PD. Kuhn W, Hummel T, Woitalla D and Müller T. Neurology 2001; 56(2): 281 – 282.

296.    Quetiapine improves involuntary movements after cerebellar stroke. Müller T, Reimer J. Journal of Neurology 2002; 249: 1320 – 1321.<

TOP